# Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy

> **NCT04124510** · PHASE3 · TERMINATED · sponsor: **Mundipharma Korea Ltd** · enrollment: 20 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Brand Name: Flutiform K-haler

## Key facts

- **NCT ID:** NCT04124510
- **Lead sponsor:** Mundipharma Korea Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-26
- **Primary completion:** 2020-09-14
- **Final completion:** 2020-09-14
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The Contract of K-haler products had been terminated between Mundipharma and provider. Therefore, this clinical trial was terminated early.
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04124510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04124510, "Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04124510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*